Fujifilm names North Carolina as location for $2 billion large-scale cell manufacturing site
CDMO subsidiary Fujifilm Diosynth Biotechnologies will operate the site which is expected to be operational in 2025
Fujifilm says it has chosen Holly Springs in North Carolina as the location for its new 200 billion yen ($2 billion) large-scale cell culture manufacturing site in the US, which the Japanese firm describes as the largest end-to-end cell culture biopharmaceutical facility in North America.
Fujifilm’s CDMO subsidiary, Fujifilm Diosynth Biotechnologies (FDB) will operate the site, which will host large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors, with additional 24 x 20,000L bioreactor capacity earmarked, based on market demand.
The facility will also provide commercial scale, automated fill-finish and assembly, packaging, and labelling services. It will employ 725 workers by the end of 2028 and is expected to be operational by spring 2025.
In a statement, Fujifilm said that after a “rigorous data-driven” evaluation process, “Holly Springs…was selected for its strong pool of technical talent, local resources and partners with the right competencies, clean energy resources, and sustainability for future growth.”
FDB already has a facility in Morrisville, North Carolina as well as other development and manufacturing plants in the US, the UK and Denmark.
At the start of this year, Fujifilm announced it was investing 4 billion yen ($40 million) in FDB to build a new process development and manufacturing facility for viral vectors and advanced therapies in the greater-Boston area, which is scheduled to begin process development operation this autumn.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance